Microcapsules for targeted drug delivery to cancer cells

A team of scientists from Peter the Great St.Petersburg Polytechnic University (SPbPU) together with their colleagues developed a method of targeted drug delivery to cancer cells. The discovery is based on the use of mesenchymal stem cells and microcapsules made of polymeric compounds. The results were published in the Biomaterials Science journal. In the future the discovery may secure more precise treatment of tumors without causing damage to healthy tissues.

Different types of tissues, including fat, muscle, cartilage, and bone, originate from mesenchymal stem cells (MSC). Moreover, these cells can migrate to tumors and react with them. The reason for it is chemokines - protein-like substances that are actively released by neoplasms. Chemokines attract the cells that have specific receptors on their surface, and the migration of such cells is aligned with the growth of chemokine concentration. The CXCR4 receptor on the surface of MSC reacts with the SDF-1 chemokine and makes the cells move closer to the tumor.

"The development of drug delivery systems based on living cells is a burning issue in biomed. This strategy provides for the use of cell cultures that are able to react with tumors. MSC are considered one of the most promising among the potential drug delivery platforms because they are relatively easy to obtain and grow in a lab," explained Timofey Karpov, a co-developer of the method, an associate at the Laboratory for Microencapsulation and Controlled Delivery of Biologically Active Compounds, RASA-SPbPU Center.

The new technology allows one to pack different biologically active substances, including anti-cancer drugs. The team selected vincristine as a sample drug because it affects different types of growths and is actively used in chemotherapy. Vincristine was put inside special microcapsules made of polymeric compounds and gold nanorods. By means of phagocytosis the capsules got into the MSC, and after that the cells were treated with infrared light that penetrates the tissues deeply without damaging them. As a result, gold particles in the capsules absorbed large amounts of energy and heated up. The heat destroyed the polymeric structures, and the drug was released into MSC. A part of vincristine remained inside, but another part got into the intercellular space and affected the tumor.

"The new technology for the synthesis of sub- and micron-sized polymeric capsules provides for the packaging of different biologically active substances. Based on it, platforms for the delivery of a wide range of antitumor substances can be developed, and drugs for different areas of modern medicine can be created. Infrared light has been widely used for a long time and is almost harmless when the irradiation parameters are set up correctly," said Timofey Karpov.

Targeted drug delivery can help reduce the toxic effects of chemotherapy by minimizing the negative impact on healthy cells.

Albert R Muslimov, Alexander S Timin, Valery R Bichaykina, Oleksii O Peltek, Timofey E Karpov, Aliaksei Dubavik, Alexandre Nominé, Jaafar Ghanbaja, Gleb B Sukhorukov, Mikhail V Zyuzin.
Biomimetic drug delivery platforms based on mesenchymal stem cells impregnated with light-responsive submicron sized carriers.
Biomater. Sci., 2020, Advance Article. doi: 10.1039/C9BM00926D.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...